Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 9Prostatic Neoplasms 8Neoplasms 5Lung Neoplasms 5Head and Neck Neoplasms 5Leukemia, Myeloid, Acute 4Hematologic Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Recurrence 2Pulmonary Disease, Chronic Obstructive 2Neoplasm Metastasis 2Lymphoma, Follicular 2Leukemia 2Colonic Neoplasms 2COVID-19 2Xerostomia 1Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Triple Negative Breast Neoplasms 1Teratoma 1Stroke 1Stomatitis 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1

Interventions

padeliporfin 3Mitomycin 2valrubicin 1temsirolimus 1pembrolizumab 1palladium-bacteriopheophorbide 1enfortumab vedotin 1abiraterone 1abemaciclib 1Tadalafil 1Standard of Care 1Radiation Dose Hypofractionation 1Prednisone 1Prednisolone 1Phosphodiesterase 5 Inhibitors 1Gemcitabine 1Fluorouracil 1Drug Therapy 1Cisplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Urogenital Neoplasms × Standard of Care × Clear all
NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡